The approval covers the prevention of COVID-19 in individuals 16 years of age and older. In addition, the vaccine remains available under FDA emergency use authorization (EUA) for people who are 12 years of age to 15 years of age, as well as for the administration of a third (booster) dose in certain immunocompromised individuals.
Get the full story at our sister site, Drug Discovery & Development.